Literature DB >> 3743524

Benzodiazepines in the treatment of children with epilepsy.

K Farrell.   

Abstract

Atonic seizures, atypical absence seizures, myoclonic seizures, tonic seizures, and infantile spasms are among the most difficult to control in children. Certain 1,4-benzodiazepines may be effective against these seizure types. Thus, clonazepam has been shown to reduce the frequency of absence, atypical absence, myoclonic, atonic, and complex partial seizures in children. Furthermore, both clonazepam and nitrazepam have been shown to be effective in the treatment of infantile spasms. However, their usefulness is limited by a deleterious effect on neurologic function, particularly on cognition. Controlled studies in animals and in adult patients and volunteers have demonstrated that clobazam has less neurotoxicity than 1,4-benzodiazepines and, in addition, may possess a psychotropic effect. Uncontrolled studies of clobazam in children suggest that this drug may be effective in the treatment of partial seizures, startle-induced seizures, infantile spasms, and Lennox-Gastaut syndrome. We studied the effect of clobazam in children whose seizures were resistant to most other antiepileptic drugs. Mental retardation was present in 80% of the children, and 62.5% had Lennox-Gastaut syndrome. Tolerance to clobazam developed in approximately one-third of patients, but this was frequently only partial and often responded to an increase in dosage. Of 50 children studied for a minimum of 3 months, seizures were controlled completely in 10 and frequency of seizures was reduced by more than 50% in a further 17. In most cases, parents observed a striking improvement in neurologic function, particularly in alertness, concentration, and balance. Thus, clobazam may be of value in the treatment of those seizures which are most difficult to control in children.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3743524     DOI: 10.1111/j.1528-1157.1986.tb05733.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

1.  Enhancement of inhibitory neurotransmission by GABAA receptors having α2,3-subunits ameliorates behavioral deficits in a mouse model of autism.

Authors:  Sung Han; Chao Tai; Christina J Jones; Todd Scheuer; William A Catterall
Journal:  Neuron       Date:  2014-03-19       Impact factor: 17.173

2.  Diagnosing idiopathic/cryptogenic epilepsy syndromes in infancy.

Authors:  N Sarisjulis; B Gamboni; P Plouin; A Kaminska; O Dulac
Journal:  Arch Dis Child       Date:  2000-03       Impact factor: 3.791

Review 3.  Clobazam.

Authors:  Yu-tze Ng; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

4.  Infantile Spasms.

Authors:  Mary L. Zupanc
Journal:  Curr Treat Options Neurol       Date:  2001-05       Impact factor: 3.598

5.  Childhood Epilepsy : Current Therapeutic Recommendations.

Authors:  J T Gilman; M Duchowny
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

Review 6.  Emerging treatments for progressive myoclonus epilepsies.

Authors:  Antonella Riva; Alberto Guglielmo; Ganna Balagura; Francesca Marchese; Elisabetta Amadori; Michele Iacomino; Berge Arakel Minassian; Federico Zara; Pasquale Striano
Journal:  Expert Rev Neurother       Date:  2020-03-17       Impact factor: 4.618

7.  Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.

Authors:  Jennifer T Leahy; Catherine J Chu-Shore; Janet L Fisher
Journal:  Neuropsychiatr Dis Treat       Date:  2011-11-11       Impact factor: 2.570

8.  Effect of clobazam as add-on antiepileptic drug in patients with epilepsy.

Authors:  Rupa Joshi; Manjari Tripathi; Pooja Gupta; Yogendra Kumar Gupta
Journal:  Indian J Med Res       Date:  2014-08       Impact factor: 2.375

Review 9.  Clobazam and Its Use in Epilepsy.

Authors:  Marius Pernea; Alastair G Sutcliffe
Journal:  Pediatr Rep       Date:  2016-06-15

10.  Treatment of Lennox-Gastaut syndrome: overview and recent findings.

Authors:  Kenou van Rijckevorsel
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.